4.4 Review

Management of Osteoarthritis: Expert Opinion on NSAIDs

期刊

PAIN AND THERAPY
卷 10, 期 2, 页码 783-808

出版社

SPRINGER INT PUBL AG
DOI: 10.1007/s40122-021-00260-1

关键词

Chronic inflammatory pain; Clinical practice; Non-steroidal anti-inflammatory drugs; Osteoarthritis; Safety

资金

  1. Alfasigma SpA

向作者/读者索取更多资源

OA is a leading cause of disability among older adults worldwide, and the goal of treatment is to alleviate inflammatory pain and improve physical function. When selecting NSAIDs, factors such as patient age, comorbidities, polypharmacy, and benefit/risk balance need to be considered to reduce the risk of adverse events. The safety profiles of different NSAIDs are not straightforward, and a multidisciplinary approach is recommended to maximize therapy efficacy while minimizing untoward effects.
Osteoarthritis (OA) is a leading cause of disability among older adults worldwide. Treatment aims are to alleviate inflammatory pain and improve physical function through non-pharmacological and pharmacological interventions. Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line therapy. However, selection is challenged by patient age, comorbidities and polypharmacy, and by the drug's benefit/risk balance, all of which together influence the risk of cardiovascular (CV), gastrointestinal (GI) and renal adverse events (AEs). While the efficacy profile of the various NSAIDs is delineated, the differences in their safety profile are not straightforward. This narrative review provides practical indications by a multidisciplinary Italian expert panel for general practitioners and specialists managing OA patients with chronic inflammatory pain; the goal is to maximize therapy efficacy while reducing untoward effects caused by inappropriate NSAID use. The discussion on the best approach to NSAIDs spanned the following topics: (1) patient evaluation: investigate pain origin, duration and components together with possible risk factors for CV, GI and renal AEs; (2) non-pharmacological interventions: the physiatrist provides a person-centered, holistic approach accounting for all patient aspects; (3) pharmacological interventions: patient profile and drugs' pharmacological properties affect NSAID selection, which drugs to be used in combination or to be avoided, formulation and therapy duration; (4) the pharmacologist's, general practitioner's and pain therapist's points of view; (5) NSAID safety: the individual baseline risk and the drug's safety profile are major determinants of CV, GI and renal risk; consider possible drug-drug interactions; (6) periodical re-evaluation of treatment response and adherence, using scales to assess pain and function.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据